ICI-164384

ICI-164384
Clinical data
Other names	N-n-Butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide
Identifiers
	IUPAC name N-butyl-11-[(7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-yl]-N-methylundecanamide;
CAS Number	98007-99-9;
PubChem CID	104772;
ChemSpider	94580;
UNII	84LT43726C;
KEGG	C14758;
ChEBI	CHEBI:40710;
ChEMBL	ChEMBL1222035;
CompTox Dashboard (EPA)	DTXSID3022376 ;
Chemical and physical data
Formula	C34H55NO3
Molar mass	525.818 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCN(C)C(=O)CCCCCCCCCC[C@@H]1CC2=C(C=CC(=C2)O)[C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)O;
	InChI InChI=1S/C34H55NO3/c1-4-5-22-35(3)32(38)15-13-11-9-7-6-8-10-12-14-25-23-26-24-27(36)16-17-28(26)29-20-21-34(2)30(33(25)29)18-19-31(34)37/h16-17,24-25,29-31,33,36-37H,4-15,18-23H2,1-3H3/t25-,29-,30+,31+,33-,34+/m1/s1; Key:BVVFOLSZMQVDKV-KXQIQQEYSA-N;

ICI-164384, also known as N-n-butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide, is a steroidal antiestrogen and a synthetic derivative of estradiol which is closely related to fulvestrant and was never marketed.^[1]^[2] It is a silent antagonist of the estrogen receptor (ER) with no intrinsic estrogenic activity and hence is a pure antiestrogen, unlike selective estrogen receptor modulators (SERMs) like tamoxifen.^[1]^[2] The drug was under development by AstraZeneca for the treatment of breast cancer but was discontinued in favor of fulvestrant,^[3] which is very similar to ICI-164384 but is more potent in comparison.^[4]